Horizon Health International Corp. Requests FDA Label Approval for Anti-Oxidant Effects

   HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS: HZHI) (the Company) is pleased to announce additional FDA Label application of Enteric Lactoferrin.

Mr. Rocco Di Fruscia, President of Horizon Health International Corp., an emerging specialty pharmaceutical company is pleased to announce that NRL Pharma Canada Inc. a wholly owned subsidiary of HORIZON, has requested FDA Label approval of the claims in the US Patent Application Number 20090082269 to commercialize this application for the Antioxidant Effects of its Enteric Lactoferrin. The analyst cites data compiled by the Nutrition Business Journal which indicates sales of Antioxidant supplements have grown from $2 billion in 1997 to $3 Billion in 2005 and will continue to grow at an enormous pace with an aging US population.

Antioxidant for lipids

In Fenton's reaction, the addition of catalysts, namely, Fe2+ and Cu+, markedly promoted hydroxyl radical production in the cell environment. Lactoferrin effectively scavenges those excess ions from the cell environment and inhibits Fenton's cycling that is responsible for hydroxyl radical production.

Antioxidant for DNA

The hydroxyl radical occasionally oxidizes nuclear and mitochondrial DNA. Oral administration of lactoferrin in Long-Evans cinnamon rats (an animal model of Wilson disease) resulted in reduced 8-hydroxy-2 OE-deoxyguanosine (8-OHdG) in mitochondrial DNA extracted from the liver. 8-OHdG is a DNA base modified by the hydroxyl radical and is known to be an oxidative stress marker.

The Company's business:

HORIZON's Subsidiary 'New Release Lactoferrin Pharma Canada Inc.' is an emerging specialty pharmaceutical company that is committed to supply its Patented delivery systems of enteric lactoferrin, and "PEG-lactoferrin". We have already introduced enteric lactoferrin products in the market as a supplemental food and have also undertaken projects to further study these products and increase their pharmaceutical applications. Since 2008, the company's proprietary enteric lactoferrin has already earned top market share amongst all lactoferrin-containing products.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.

Contacts: Horizon Health International Corp. Rocco Di Fruscia President & CEO 514 586 3799 [e-mail] www.horizonhealthinternational.com